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Abstract: Background: We investigated the mutational landscape of skin tumors in patients with
Muir-Torre Syndrome (MTS) a hereditary autosomal dominant mismatch repair disorder of increased
cancer susceptibility, and examined mutations other than in the DNA mismatch repair (MMR) genes.
Methods: This retrospective single-center case series included seven patients with the diagnosis
of Muir-Torre Syndrome with precise medical history and family history. Mutational analysis of
tumor samples Formalin-fixed paraffin-embedded tissue blocks of skin lesions associated with Muir-
Torre Syndrome were used for further analysis. All skin tumors were analyzed with the Oncomine
Comprehensive Assay v3 (Life Technologies), which includes 161 of the most relevant cancer driver
genes. Results: Eleven skin neoplasms (nine sebaceous tumors, one melanoma, one cutaneous
squamous cell carcinoma) were diagnosed in seven patients. In two patients, visceral malignancies
preceded the diagnosis of the skin tumors and one patient was diagnosed with a visceral malignancy
after a sebaceous tumor. History of familial cancer of Lynch Syndrome (LS) was reported in three
patients. The most frequently detected mutation was in the MSH2 gene, followed by mutations in
the NOTCH1/2 and TP53 gene. Conclusion, this study provides a molecular analysis of Muir-Torre
Syndrome associated and non-associated skin tumors in patients with Muir-Torre Syndrome. Patients
with sebaceous lesions should undergo microsatellite instability analysis and accurate evaluation of
personal and family history to detect a possible Muir-Torre syndrome. As secondary malignancies
may appear years after the first occurrence of sebaceous tumors, lifelong screening is mandatory.
Keywords: Muir-Torre Syndrome; family history; next-generation sequencing; molecular analysis
1. Introduction
Muir-Torre Syndrome (MTS) represents a distinct variant of Lynch Syndrome (LS),
previously referred to as hereditary nonpolyposis colorectal cancer (HNPCC) [1]. It is
characterized as an inherited autosomal dominant disorder with early cancer susceptibility,
which manifests with sebaceous adenomas or carcinomas, keratoacanthomas and tumors
of visceral organs. Among visceral tumors, colorectal cancer is the most common with
the prevalence of 0.5–5% [2]. Further associated malignancies are endometrial carcinoma,
gastric cancer, tumors of the small bowel, transitional cell carcinoma (ureter and renal
pelvis), ovarian and pancreatic tumors [3].
From a genetic perspective, all subtypes of LS underlie a microsatellite instability. This
leads to an increased likelihood of the occurrence of mutations in genes, which results in
oncogenic propensity [4,5]. Distinct genetic mutations are described for the MTS, most of
which derive from single case studies with particular attention to mismatch repair gene
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mutations. So far, genetic alterations associated with MTS have been described for the DNA
mismatch repair (MMR) genes MLH1, MSH2, MSH6, PMS2, MLH3 and the non-MMR
gene EBCAM, which epigenetically silences the closely linked MSH2 gene [6]. Patients
with MLH1 and MSH2 gene mutations tend to have a higher risk for malignant tumors
compared to patients with a MSH6 gene mutation [7–9]. In 90% of LS patients, MLH1 and
MSH2 mutation are responsible for malignant tumors with a ratio of 1:1. Only 7–10% of the
LS patients develop malignancy due to MSH6 mutation, and 5% due to PMS2 mutation.
In contrast, 90% of the mutations in MTS occur in the MSH2 gene, which has also shown
to be responsible for more extracolonic and multiple primary cancers as compared to the
MLH1 gene [10].
We aimed to detect and compare other responsible genetic alterations in MTS asso-
ciated and non-associated skin tumors in our MTS patients cohort, as sebaceous tumors
with locoregional and distant metastasis of up to 14% to 25% have an aggressive potential
and targeted therapy in sebaceous carcinoma has not been given much thought [11]. To ad-
dress this, we collected clinical information, family history and performed next-generation
sequencing (NGS)-based multiple-biomarker assay on sebaceous and non-sebaceous tu-
mors of seven MTS patients to identify responsible mutations and to compare them to the
reported data.
2. Materials and Methods
2.1. Introduction
The database (KISIM) from the University Hospital of Zurich was searched for patients
with the Diagnosis of Muir-Torre Syndrome. Patients who fulfilled the diagnostic criteria
from the revised Bethesda Guidelines were included into analysis [12]. Retrospective data
of seven patients, including their medical and family history, were analyzed and next-
generation sequencing was performed on the sebaceous and non-sebaceous skin tumors of
these patients.
2.2. Mutational Analysis of Tumor Samples
Formalin-fixed paraffin-embedded (FFPE) tissue blocks of skin lesions associated
and non-associated with MTS were used for further analysis. Representative tumor areas
were marked by a dermatopathologist. Punch biopsies of 0.4 mm in diameter were taken
from the corresponding areas of the FFPE blocks. DNA/RNA isolation was performed
using the automated Maxwell system (Promega, Madison, WI, USA) according to the
manufacturer’s manual. Library preparation was performed using 20 ng of DNA/RNA
and the Oncomine Comprehensive Assay v3 (Life Technologies, Waltham, MA, USA). The
Oncomine Comprehensive v3 assay was chosen as to that date it was the largest gene panel
offered at our institution. The targeted genes are displayed in Table S1. It includes the most
important oncogenic drivers and tumor suppressors across various types of cancers. The
libraries were subsequently sequenced on the S5 sequencer (Life Technologies, Waltham,
MA, USA). Data analysis was conducted using the Ion Reporter Software version 5.10 (Life
Technologies, Waltham, MA, USA).
The study was conducted at the University Hospital of Zurich in Switzerland. The




Seven patients were included in the analysis. The median age at diagnosis of the first
MTS associated malignancy was 61 years (range 45–75 years). Five of the patients were
male, two were female (Table 1).
Genes 2021, 12, 781 3 of 12
Table 1. Demographic data.
Total Number of Patients 7
Male 5
Female 2
Age (range) 61 (45–75)
Localization
Non- head and neck 7
Head and neck 4
Tumor type (total number) 11
Sebaceous adenoma 2
Sebaceoma 1
Solid-cystic sebaceous neoplasm 1
Sebaceous carcinoma 4
Tumor with sebaceous differentiation 1
Squamous cell carcinoma 1
Melanoma 1
3.2. Medical History
In two patients, visceral malignancies preceded the diagnosis of the skin tumors. In
our cohort the most frequent visceral malignancies were urogenital tumors (two patients;
22%). One patient was diagnosed with a small lymphocytic lymphoma due to the following
staging after diagnosis of a sebaceous adenoma.
3.3. Sebaceous Lesions and Other Cutaneous Tumors
Eleven skin neoplasms were diagnosed in seven patients. Seven (64%) were located
outside the head and neck region and four (36%) in the head and neck region. A photograph
and histological presentation of a sebaceoma of patient 2 is illustrated in Figures 1 and 2.
Figure 1. Abdominal sebaceoma patient 2. Faintly pinkish to skin-colored papule with dermoscopi-
cally yellowish ovoid areas and arborizing vessels.
Figure 2. Histology of a sebaceoma abdomen patient 2 (hematoxylin and eosin stain). Circumscribed
basaloid tumor with sebaceous differentiation and mitosis.
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One patient was diagnosed with both—MTS associated and non-associated skin
tumors. Additionally to a sebaceous tumors, he was diagnosed with a squamous cell
carcinoma (SCC) and melanoma.
Further data are displayed in Tables 1 and 2.








1. Sebaceous carcinoma (63)
2. Tumor with sebaceous
differentiation (63)





Uncle (mother’s side): Lung-
and brain tumor










3 Sebaceous carcinoma (63) Renal cell carcinoma (58) - Hip
4 Solid-cystic sebaceous tumor (62) - - Back
5 Sebaceous carcinoma (65) - - Back
6 Sebaceous carcinoma (75) - - Back
7 Sebaceous adenoma (72)
Small lymphocytic
lymphoma
Brother: Lung tumor Cheek
3.4. Family History
History of familial cancer of LS was reported in three patients. Seven of the tumors
were associated with MTS and one tumor had no association with MTS.
The pedigree of the affected families is illustrated in Figure 3.
3.5. Tumor Mutations
The most frequently detected mutation in all analyzed skin tumors was in the MSH2
gene and was found in six patients (86%). The only other MMR gene mutation was MLH1
and was only present in one patient (14%). The other most frequent mutations were in the
NOTCH1, NOTCH2 and in the TP53 genes and were found in three (43%), two (29%) and
two patients (29%), respectively.
The patient diagnosed with multiple sebaceous skin lesions (sebaceous carcinoma,
sebaceous adenoma, tumor with sebaceous differentiation) additionally had a SCC and a
melanoma in his history. All sebaceous lesions displayed NOTCH1 and NOTCH2 mutations.
The tumor with sebaceous differentiation in this patient showed an MMR mutation in
the MLH1 gene, but this was missing in the other sebaceous tumors. The melanoma and
sebaceous carcinoma showed none of the above-mentioned mutations.
The detected mutations are summarized in Tables 3 and 4.
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Figure 3. (a) Pedigree of patient 1 shows the autosomal dominant transmission of skin and visceral tumors; (b) patient 7
with MTS associated tumors in family members (c); patient 7 has a brother with a lung tumor; (d) Legend.
Table 3. Most frequent mutations.
Mutated Gene MSH2 MLH1 NOTCH1 NOTCH2 TP53
Total number (%) 6 (86%) 1 (14%) 3 (43%) 2 (29%) 2 (29%)
Histological type
SC 4 - 2 2 1
SCS 1 - 1 - 1
SE 1 - - - -
SA - 1 - - -
Localization
Non-head and neck 5 1 2 1 2
Head and neck 1 - 1 1 -
Abbreviations: SC, sebaceous carcinoma; SCS, solid-cystic sebaceous neoplasm; SE, sebaceoma; SA, sebaceous
adenoma.
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Coverage Exon Transcript Coding ACMG Class
1 m SC (80%) chr1:120462204 NOTCH2 42 p.(Arg1838*) 2000 31 NM_024408.3 c.5512C>T Pathogenic (class 5)
chr5:67591079 PIK3R1 46 p.(Glu558fs) 1992 13 NM_181523.2 c.1674_1675del Uncertain significance (class 3)
chr9:139404265 NOTCH1 45 p.(Cys963*) 1985 18 NM_017617.4 c.2889C>A Likely pathogenic (class 4)
chr9:139405616 NOTCH1 44 p.(Thr859fs) 1923 16 NM_017617.4 c.2574_2575ins Likely pathogenic (class 4)
TDS (70%) chr1:120491661 NOTCH2 41 p.(Ser856fs) 1623 16 NM_024408.3 c.2566_2567del Likely pathogenic (class 4)
chr3:37090403 MLH1 43 p.(Trp666*) 2000 18 NM_000249.3 c.1998G>A Pathogenic (class 5)
chr3:47103763 SETD2 40 p.(Asp2064fs) 1043 14 NM_014159.6 c.6181_6182del Uncertain significance (class 3)
chr9:139397730 NOTCH1 39 p.(Gln1691*) 810 27 NM_017617.4 c.5071C>T Pathogenic (class 5)
chr10:123279674 FGFR2 35 p.(Pro253His) 1677 7 NM_000141.4 c.758C>A Likely pathogenic (class 4)
chr16:3646385 SLX4 5 p.(Gln565*) 519 8 NM_032444.3 c.1693C>T Pathogenic (class 5)
M (50%) chr16:2135234 TSC2 5 p.(Gln1525*) 366 36 NM_000548.4 c.4573C>T Pathogenic (class 5)
SA (80%) chr1:120464352 NOTCH2 9 p.(Gln1765fs) 1939 29 NM_024408.3 c.5293delC Likely pathogenic (class 4)
SCC (70%) chr9:139417303 NOTCH1 13 p.(Pro247fs) 1007 4 NM_017617.4 c.740_741ins Likely pathogenic (class 4)
chr4:153249385 FBXW7 22 p.(Arg465Cys) 2000 9 NM_033632.3 c.1393C>T Likely pathogenic (class 4)
chr17:37687555 CDK12 27 p.(Gly1487*) 2000 14 NM_016507.3 c.4459G>T Uncertain significance (class 3)
chr17:37879658 ERBB2 30 p.(Arg678Gln) 1999 17 NM_004448.3 c.2033G>A Uncertain significance (class 3)
2 f SE (70%) chr2:47698134 MSH2 42 p.(Asn566fs) 1907 11 NM_000251.2 c.1697del Pathogenic (class 5)
chr7:55241677 EGFR 16 p.(Glu709Lys) 1997 18 NM_005228.4 c.2125G>A Uncertain significance (class 3)
3 m SC (80%) chr2:47630386 MSH2 59 p.(Phe22fs) 1835 1 NM_000251.2 c.62_63ins Pathogenic (class 5)
4 m SCS (80%) chr2:47637361 MSH2 42 p.(Tyr165*) 1999 3 NM_000251.2 c.495T>A Pathogenic (class 5)
chr3:178952085 PIK3CA 36 p.(His1047Arg) 1658 21 NM_006218.3 c.3140A>G Pathogenic (class 5)
chr9:139418362 NOTCH1 25 p.(Asn70fs) 4684 3 NM_017617.4 c.209_210ins Likely pathogenic (class 4)










Coverage Exon Transcript Coding ACMG Class
chr9:139418364 NOTCH1 40 p.(Asn70fs) 1996 3 NM_017617.4 c.207_208ins Likely pathogenic (class 4)
chr10:89711899 PTEN 46 p.(Arg173Cys) 1797 6 NM_000314.6 c.517C>T Likely pathogenic (class 4)
chr12:133202239 POLE 17 p.(Gln2217*) 128 47 NM_006231.3 c.6649C>T Pathogenic (class 5)
chr17:7578403 TP53 39 p.(Cys176Tyr) 1998 5 NM_000546.5 c.527G>A Likely pathogenic (class 4)
chr17:29665125 NF1 43 p.(Gln2263*) 2000 45 NM_001042492.2 c.6787C>T Pathogenic (class 5)
5 f SC (60%) chr2:47693918 MSH2 42 p.(Gln545*) 144 10 NM_000251.2 c.1632_1633del Pathogenic (class 5)
6 m SC (70%) chr2:47693799 MSH2 36 p.(Pro507fs) 2283 10 NM_000251.2 c.1518_1519ins Pathogenic (class 5)
chr2:47693804 MSH2 72 p.(Pro507fs) 1200 10 NM_000251.2 c.1518_1519ins Pathogenic (class 5)
chr16:23637644 PALB2 4 p.(Ile887fs) 637 7 NM_024675.3 c.2659_2660del Uncertain significance (class 3)
7 m SA (30%) chr1:120466424 NOTCH2 40 p.(Arg1567fs) 1944 26 NM_024408.3 c.4694_4695ins Likely pathogenic (class 4)
chr2:47698188 MSH2 82 p.(Asn583fs) 1984 11 NM_000251.2 c.1747_1748del Pathogenic (class 5)
chr9:139402690 NOTCH1 41 p.(Arg1107*) 901 20 NM_017617.4 c.3319C>T Pathogenic (class 5)
chr11:534289 HRAS 43 p.(Gly12Ser) 1188 2 NM_001130442.2 c.34G>A Uncertain significance (class 3)
Abbreviations: P, patient number; SC, sebaceous carcinoma; TSD, tumor with sebaceous differentiation; M, melanoma; SA, sebaceous adenoma; SCC, squamous cell carcinoma; SE, sebaceoma; SCS, solid-cystic
sebaceous neoplasm.
Genes 2021, 12, 781 8 of 12
4. Discussion
4.1. Introduction
In this presented work, we investigated mutations other than in the MMR genes
in sebaceous tumors and non-MTS associated skin lesions in patients diagnosed with
Muir-Torre Syndrome. We showed which concomitant mutations may arise in these
tumors, providing options for targeted therapy in advanced sebaceous tumors. With only
few case reports in the literature, we furthermore examined the family histories of the
affected patients, to highlight the importance of a precise medical history for a presumptive
diagnosis of MTS in patients with sebaceous tumors [13–15].
4.2. Demographic Data
Sebaceous hyperplasia with frequent occurrence in the general population stands in
contrast to sebaceous tumors, which are rare in general population, but often present in
patients with MTS [16]. Most commonly, patients are diagnosed with sebaceous adenoma
followed by sebaceous epithelioma and sebaceous carcinoma [17]. Concordant to previous
data, we found sebaceous skin neoplasm in MTS patients to be more frequent outside the
head and neck region.
4.3. Medical History
In over half of the cases, sebaceous skin lesions develop after diagnosis of a visceral ma-
lignancy, while in 22% of cases they precede visceral malignancies by up to 25 years [18,19].
This is reflected in our patient cohort with one patient being diagnosed with small lym-
phocytic lymphoma as he was screened for visceral malignancies after the diagnosis of a
sebaceous adenoma. In two patients, visceral malignancies preceded the diagnosis of a se-
baceous lesion. Apart from sebaceous tumors, squamous cell carcinoma (SSC) was reported
to be associated with MMR mutations [20,21]. Additionally to sebaceous tumors, patient 1
was diagnosed with SCC and melanoma, both of which lacked MMR mutation and were
most likely due to sporadic mutation. G. Ponti et al. [22] identified nine melanomas in a
collective of 1057 LS patients. In only one case, MSH2 mutation was confirmed, which
indicates that the MMR genes are not a driving molecular mechanism in the genesis of
melanoma, although deletions of the MMR genes can be present in sporadic melanoma [22].
One patient in our study group, was treated with cyclosporine due to a severe psoriasis
vulgaris 16 years prior to the diagnosis of a solid cystic sebaceous tumor. As a switch of
cyclosporine to sirolimus can decrease the frequency of sebaceous lesions, this should be
considered in patients with immunosuppressive therapy [23,24].
4.4. Family History
We found a positive family history in three patients for visceral malignancies associ-
ated with MTS. Families with history of MTS-associated tumors, such as colorectal cancer,
should undergo further genetic testing, as immunohistochemistry without family history
of colorectal cancers is inferior in sensitivity and specificity as well as in the positive and
negative predictive values [25]. Dermatofibrosarcoma and cutaneous T cell lymphoma
(CTCL), as found in the relative of patient 2, who had a sebaceoma with a MSH2 mutation,
have been described in association with Lynch families with germline MSH2 mutations [26].
There are also case reports of patients with CTCL, such as mycosis fungoides (MF) with
MTS [27]. Scarisbrick et al. found microsatellite instability in 27% of patients with MF.
Reduced expression of the hMLH1 protein was found in 56% and normal expression of the
hMLH1 protein in patients without MSI, suggesting that hMLH1 promoter methylation
may provide a potential future therapeutic target [28].
4.5. Mutational Analysis
In our collective, most commonly mutations in the mismatch repair protein (MMR)
in the MSH2 gene were detected (six patients; 86%), which is consistent with the current
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literature [10,29]. Besides these MMR mutations, we found diverse further mutations:
The second most frequently mutated gene was NOTCH1, present in three patients. Re-
flecting the tumor suppressing function of NOTCH signaling in keratinocytes, loss of
function mutations are found in SCC of the head and neck, basal cell carcinoma but also
in visceral carcinomas, such as breast cancer, small cell lung carcinoma and urothelial
carcinoma [30]. In contrast, gain of function mutations in the NOTCH genes have been
described for different lymphomas [30–32]. Interestingly, patient 7 was diagnosed with
small lymphocytic lymphoma after diagnosis of a sebaceous adenoma, which comprised
mutations in NOTCH1 and 2 additionally to the MSH2 gene. However, mutational analysis
of the bone marrow using the “TruSight Myeloid Sequencing Panel” showed no mutations.
Mutations in TP53, coding for the tumor suppressor protein p53, for instance, was found
in two patients. Yongyang Bao et al. found TP53 mutations in 83% of the patients with
sebaceous carcinoma of the eyelid [33]. This result is similar to previous studies of seba-
ceous carcinomas, which display a high rate for TP53 mutations [34,35]. Patient 4 had a
solid-cystic sebaceous tumor, with a NF1 mutation. Somatic mutations in the NF1 gene
are found in a wide variety of malignant neoplasms that are not associated with Neurofi-
bromatosis type 1 such as desmoplastic, cutaneous and mucosal melanoma and various
visceral malignancies [36]. Especially in desmoplastic melanoma, NF1 gene mutations are
commonly observed with frequencies of up to 93% [37]. Tetzlaff and colleagues found two
patients with NF1 gene mutations in a collective of 27 sebaceous carcinomas [35]. An EGFR
mutation was identified in one patient with a sebaceoma of the abdomen. EGFR mutations
in sebaceous tumors are described in previous studies. Harvey et al. found, in a collective
of 24 sebaceous lesions, nine to have an EGFR mutation [34]. Regarding the mutations we
found in our patients collective, targeted therapy has been used with success in adenocarci-
noma of the lung with EGFR mutations, PIK3 inhibitors in stage four melanoma or MEK
inhibitors in inoperable plexiform neurofibromas with NF1 mutations [38–40].
4.6. Diagnostic Criteria
Our findings highlight the necessity of physical examination of the skin and the lymph
nodes, as well as the common screening recommendations for patients with MTS and their
first-degree relatives. This includes annually physical examination (including breast in
women and testicular and prostate in men), laboratory tests, colonoscopy every one to
two years from the age of 25 years or five years before the youngest age of diagnosis
of colorectal cancer in the family, gastroscopy and ultrasonography every one to two
years [41]. As an association between sebaceous tumors and iatrogenic immunosuppression
is described in the literature, particularly under the treatment of cyclosporine, patients
under immunomodulatory therapy should receive regularly physical examinations and
sebaceous lesions should be analyzed for microsatellite instability, as it could unmask a
latent Muir-Torre phenotype [23]. In accordance with the Bethesda guidelines, patients
diagnosed with colorectal cancer at an early age (<50 years), with a suggestive personal
(presence of synchronous, metachronous colorectal, or other Lynch-associated tumors) or
family history, should undergo further genetic testing [12].
4.7. Limitations
The limitation of the study is the restriction of patients number and tumor samples’
origin. Furthermore, the evaluation of the precise mutations being responsible for the
visceral tumors in our patients collective would be important to draw a connection to the
skin tumors. As only skin samples were analyzed for MMR mutations, and we did not look
for germline mutations, we cannot rule out that the here described mutations are somatic.
Germline mutations in the MMR genes could provide information about the cause of the
tumors. Further molecular analysis of the tumors in the patients’ relatives or genetic testing
of normal tissue or blood of the patients could give an indication of possible inherited
mutations causing the Muir-Torre syndrome in this family.
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5. Conclusions
This study provides an extensive molecular analysis of MTS associated and non-
associated skin tumors in patients with MTS. We showed how different MTS-associated
tumors can appear throughout generations in patients with mutations in the MSH genes.
Therefore, along with MSI analysis, accurate evaluation of personal and family history is
mandatory for patients with sebaceous lesions to detect a possible Muir-Torre syndrome.
As secondary malignancies may appear years after the first occurrence of sebaceous tumors,
lifelong screening is required. Furthermore, the importance of physical examination of the
skin is undeniable.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
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